EASL Clinical Practice Guidelines

References

[1]Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924926
CrossRef | PubMed

[2]Chazouillres, O. and Housset, C. Intrahepatic cholestasis. in: J. Rods (Ed.) Textbook of hepatology: from basic science to clinical practice. 3rd ed. Blackwell, Oxford; 2007: 14811500

[3]Heathcote, E.J. Diagnosis and management of cholestatic liver disease. Clin Gastroenterol Hepatol. 2007; 5: 776782
PubMed | Scopus (15)

[4]Freeman, M.L., Nelson, D.B., Sherman, S., Haber, G.B., Herman, M.E., Dorsher, P.J. et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996; 335: 909918
CrossRef | PubMed | Scopus (1312)

[5]Ludwig, J. Idiopathic adulthood ductopenia: an update. Mayo Clin Proc. 1998; 73: 285291
PubMed

[6]Heathcote, E.J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000; 31: 10051013
CrossRef | PubMed

[7]Metcalf, J.V., Mitchison, H.C., Palmer, J.M., Jones, D.E., Bassendine, M.F., and James, O.F. Natural history of early primary biliary cirrhosis. Lancet. 1996; 348: 13991402
Abstract | Full Text | Full Text PDF | PubMed | Scopus (243)

[8]Invernizzi, P., Lleo, A., and Podda, M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis. 2007; 27: 161172
CrossRef | PubMed | Scopus (43)

[9]Vergani, D., Alvarez, F., Bianchi, F.B., Cancado, E.L., Mackay, I.R., Manns, M.P. et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004; 41: 677683
Abstract | Full Text | Full Text PDF | PubMed | Scopus (131)

[10]Ludwig, J., Dickson, E.R., and McDonald, G.S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978; 379: 103112
CrossRef | PubMed

[11]Scheuer, P.J. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J. 1983; 59: 106115
CrossRef | PubMed

[12]Beuers, U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 318328
CrossRef | PubMed | Scopus (132)

[13]Poupon, R.E., Balkau, B., Eschwege, E., and Poupon, R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991; 324: 15481554
CrossRef | PubMed

[14]Heathcote, E.J., Cauch-Dudek, K., Walker, V., Bailey, R.J., Blendis, L.M., Ghent, C.N. et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994; 19: 11491156
CrossRef | PubMed

[15]Lindor, K.D., Dickson, E.R., Baldus, W.P., Jorgensen, R.A., Ludwig, J., Murtaugh, P.A. et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994; 106: 12841290
PubMed

[16]Combes, B., Carithers, R.L. Jr., Maddrey, W.C., Lin, D., McDonald, M.F., Wheeler, D.E. et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995; 22: 759766
PubMed

[17]Pares, A., Caballeria, L., Rodes, J., Bruguera, M., Rodrigo, L., Garcia-Plaza, A. et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol. 2000; 32: 561566
PubMed | Scopus (138)

[18]Corpechot, C., Carrat, F., Bonnand, A.M., Poupon, R.E., and Poupon, R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000; 32: 11961199
CrossRef | PubMed

[19]Poupon, R.E., Lindor, K.D., Cauch-Dudek, K., Dickson, E.R., Poupon, R., and Heathcote, E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997; 113: 884890
PubMed | Scopus (354)

[20]Goulis, J., Leandro, G., and Burroughs, A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999; 354: 10531060
Abstract | Full Text | Full Text PDF | PubMed | Scopus (189)

[21]Gong, Y., Huang, Z., Christensen, E., and Gluud, C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol. 2007; 102: 17991807
CrossRef | PubMed | Scopus (47)

[22]Shi, J., Wu, C., Lin, Y., Chen, Y.X., Zhu, L., and Xie, W.F. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006; 101: 15291538
CrossRef | PubMed | Scopus (42)

[23]Lindor, K.D., Poupon, R., Heathcote, E.J., and Therneau, T. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 2000; 355: 657658
Abstract | Full Text | Full Text PDF | PubMed

[24]Angulo, P., Dickson, E.R., Therneau, T.M., Jorgensen, R.A., Smith, C., DeSotel, C.K. et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol. 1999; 30: 830835
PubMed | Scopus (53)

[25]Corpechot, C., Carrat, F., Bahr, A., Chretien, Y., Poupon, R.E., and Poupon, R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005; 128: 297303
Abstract | Full Text | Full Text PDF | PubMed | Scopus (156)

[26]ter Borg, P.C., Schalm, S.W., Hansen, B.E., and van Buuren, H.R. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006; 101: 20442050
CrossRef | PubMed | Scopus (47)

[27]Pares, A., Caballeria, L., and Rodes, J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006; 130: 715720
Abstract | Full Text | Full Text PDF | PubMed | Scopus (151)

[28]Corpechot, C., Abenavoli, L., Rabahi, N., Chretien, Y., Andreani, T., Johanet, C. et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48: 871877
CrossRef | PubMed | Scopus (81)

[29]Mitchison, H.C., Bassendine, M.F., Malcolm, A.J., Watson, A.J., Record, C.O., and James, O.F. A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss. Hepatology. 1989; 10: 420429
CrossRef | PubMed

[30]Leuschner, M., Guldutuna, S., You, T., Hubner, K., Bhatti, S., and Leuschner, U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol. 1996; 25: 4957
PubMed | Scopus (73)

[31]Leuschner, M., Maier, K.P., Schlichting, J., Strahl, S., Herrmann, G., Dahm, H.H. et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999; 117: 918925
PubMed | Scopus (105)

[32]Rautiainen, H., Karkkainen, P., Karvonen, A.L., Nurmi, H., Pikkarainen, P., Nuutinen, H. et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005; 41: 747752
CrossRef | PubMed | Scopus (69)

[33]Angulo, P., Jorgensen, R.A., Keach, J.C., Dickson, E.R., Smith, C., and Lindor, K.D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000; 31: 318323
CrossRef | PubMed

[34]Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., and Sauerbruch, T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003; 38: 196202
CrossRef | PubMed | Scopus (48)

[35]Christensen, E., Neuberger, J., Crowe, J., Altman, D.G., Popper, H., Portmann, B. et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology. 1985; 89: 10841091
PubMed

[36]Lombard, M., Portmann, B., Neuberger, J., Williams, R., Tygstrup, N., Ranek, L. et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology. 1993; 104: 519526
PubMed

[37]Hendrickse, M.T., Rigney, E., Giaffer, M.H., Soomro, I., Triger, D.R., Underwood, J.C. et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology. 1999; 117: 400407
Abstract | Full Text | Full Text PDF | PubMed | Scopus (57)

[38]Gonzalez-Koch, A., Brahm, J., Antezana, C., Smok, G., and Cumsille, M.A. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol. 1997; 27: 143149
PubMed | Scopus (33)

[39]Combes, B., Emerson, S.S., Flye, N.L., Munoz, S.J., Luketic, V.A., Mayo, M.J. et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology. 2005; 42: 11841193
CrossRef | PubMed | Scopus (50)

[40]Hoofnagle, J.H., Davis, G.L., Schafer, D.F., Peters, M., Avigan, M.I., Pappas, S.C. et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology. 1986; 91: 13271334
PubMed

[41]Talwalkar, J.A., Angulo, P., Keach, J.C., Petz, J.L., Jorgensen, R.A., and Lindor, K.D. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2005; 39: 168171
CrossRef | PubMed

[42]Vuoristo, M., Farkkila, M., Karvonen, A.L., Leino, R., Lehtola, J., Makinen, J. et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology. 1995; 108: 14701478
PubMed | Scopus (57)

[43]Poupon, R.E., Huet, P.M., Poupon, R., Bonnand, A.M., Nhieu, J.T., and Zafrani, E.S. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCAPBC Study Group. Hepatology. 1996; 24: 10981103
CrossRef | PubMed

[44]Neuberger, J., Christensen, E., Portmann, B., Caballeria, J., Rodes, J., Ranek, L. et al. Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut. 1985; 26: 114119
CrossRef | PubMed

[45]Gong, Y., Klingenberg, S.L., and Gluud, C. Systematic review and meta-analysis: d-penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosisCochrane Hepato-Biliary Group. Aliment Pharmacol Ther. 2006; 24: 15351544
CrossRef | PubMed | Scopus (8)

[46]The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol 1993;17:22735.

[47]McCormick, P.A., Scott, F., Epstein, O., Burroughs, A.K., Scheuer, P.J., and McIntyre, N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol. 1994; 21: 496499
PubMed | Scopus (19)

[48]Angulo, P., Patel, T., Jorgensen, R.A., Therneau, T.M., and Lindor, K.D. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000; 32: 897900
CrossRef | PubMed

[49]Stojakovic, T., Putz-Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V. et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology. 2007; 46: 776784
CrossRef | PubMed | Scopus (38)

[50]Leuschner, M., Holtmeier, J., Ackermann, H., and Leuschner, U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol. 2002; 14: 13691376
CrossRef | PubMed | Scopus (17)

[51]Iwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M. et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008; 38: 557564
CrossRef | PubMed | Scopus (32)

[52]Invernizzi, P., Alvaro, D., Crosignani, A., Gaudio, E., and Podda, M. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology. 2004; 39: 11751176
CrossRef | PubMed | Scopus (14)

[53]Mason, A.L., Farr, G.H., Xu, L., Hubscher, S.G., and Neuberger, J.M. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004; 99: 23482355
CrossRef | PubMed | Scopus (28)

[54]MacQuillan, G.C. and Neuberger, J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis. 2003; 7: 941956
PubMed | Scopus (23)

[55]Milkiewicz, P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis. 2008; 12: 461472
PubMed | Scopus (14)

[56]Gautam, M., Cheruvattath, R., and Balan, V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12: 18131824
CrossRef | PubMed | Scopus (97)

[57]Chazouilleres, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., and Poupon, R. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998; 28: 296301
CrossRef | PubMed | Scopus (295)

[58]Lohse, A.W., zum Buschenfelde, K.H., Franz, B., Kanzler, S., Gerken, G., and Dienes, H.P. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999; 29: 10781084
CrossRef | PubMed

[59]Woodward, J. and Neuberger, J. Autoimmune overlap syndromes. Hepatology. 2001; 33: 9941002
CrossRef | PubMed | Scopus (70)

[60]Beuers, U. and Rust, C. Overlap syndromes. Semin Liver Dis. 2005; 25: 311320
CrossRef | PubMed | Scopus (63)

[61]Heathcote, E.J. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002; 97: 10901092
CrossRef | PubMed

[62]Alvarez, F., Berg, P.A., Bianchi, F.B., Bianchi, L., Burroughs, A.K., Cancado, E.L. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31: 929938
PubMed | Scopus (1374)

[63]Talwalkar, J.A., Keach, J.C., Angulo, P., and Lindor, K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002; 97: 11911197
CrossRef | PubMed

[64]Chazouilleres, O., Wendum, D., Serfaty, L., Rosmorduc, O., and Poupon, R. Long term outcome and response to therapy of primary biliary cirrhosisautoimmune hepatitis overlap syndrome. J Hepatol. 2006; 44: 400406
PubMed | Scopus (81)

[65]Hennes, E.M., Zeniya, M., Czaja, A.J., Pares, A., Dalekos, G.N., Krawitt, E.L. et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008; 48: 169176
CrossRef | PubMed | Scopus (320)

[66]Yamamoto, K., Terada, R., Okamoto, R., Hiasa, Y., Abe, M., Onji, M. et al. A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver disease. J Gastroenterol. 2003; 38: 5259
CrossRef | PubMed | Scopus (25)

[67]Poupon, R., Chazouilleres, O., Corpechot, C., and Chretien, Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006; 44: 8590
CrossRef | PubMed | Scopus (62)

[68]Czaja, A.J. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996; 125: 588598
CrossRef | PubMed

[69]Rust, C. and Beuers, U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol. 2008; 14: 33683373
CrossRef | PubMed | Scopus (54)

[70]Silveira, M.G., Talwalkar, J.A., Angulo, P., and Lindor, K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007; 102: 12441250
CrossRef | PubMed | Scopus (42)

[71]Joshi, S., Cauch-Dudek, K., Wanless, I.R., Lindor, K.D., Jorgensen, R., Batts, K. et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002; 35: 409413
CrossRef | PubMed | Scopus (88)

[72]Csepregi, A., Rocken, C., Treiber, G., and Malfertheiner, P. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006; 12: 13621366
PubMed

[73]Duclos-Vallee, J.C., Hadengue, A., Ganne-Carrie, N., Robin, E., Degott, C., and Erlinger, S. Primary biliary cirrhosisautoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci. 1995; 40: 10691073
CrossRef | PubMed

[74]Maggs, J.R. and Chapman, R.W. An update on primary sclerosing cholangitis. Curr Opin Gastroenterol. 2008; 24: 377383
CrossRef | PubMed | Scopus (43)

[75]Karlsen, T.H., Schrumpf, E., and Boberg, K.M. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol. 2007; 13: 54215431
PubMed

[76]Abdalian, R. and Heathcote, E.J. Sclerosing cholangitis: a focus on secondary causes. Hepatology. 2006; 44: 10631074
CrossRef | PubMed | Scopus (76)

[77]Broome, U., Olsson, R., Loof, L., Bodemar, G., Hultcrantz, R., Danielsson, A. et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996; 38: 610615
CrossRef | PubMed

[78]Chapman, R.W., Arborgh, B.A., Rhodes, J.M., Summerfield, J.A., Dick, R., Scheuer, P.J. et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980; 21: 870877
CrossRef | PubMed

[79]Tischendorf, J.J., Hecker, H., Kruger, M., Manns, M.P., and Meier, P.N. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol. 2007; 102: 107114
CrossRef | PubMed | Scopus (95)

[80]Boberg, K.M., Fausa, O., Haaland, T., Holter, E., Mellbye, O.J., Spurkland, A. et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology. 1996; 23: 13691376
CrossRef | PubMed

[81]Mendes, F.D., Jorgensen, R., Keach, J., Katzmann, J.A., Smyrk, T., Donlinger, J. et al. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2006; 101: 20702075
CrossRef | PubMed | Scopus (109)

[82]Hov, J.R., Boberg, K.M., and Karlsen, T.H. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol. 2008; 14: 37813791
CrossRef | PubMed | Scopus (31)

[83]Ludwig, J. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol. 1989; 13: 4349
PubMed

[84]van de Meeberg, P.C., Portincasa, P., Wolfhagen, F.H., van Erpecum, K.J., and VanBerge-Henegouwen, G.P. Increased gall bladder volume in primary sclerosing cholangitis. Gut. 1996; 39: 594599
CrossRef | PubMed

[85]Said, K., Glaumann, H., and Bergquist, A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol. 2008; 48: 598605
PubMed | Scopus (36)

[86]Lee, Y.M. and Kaplan, M.M. Primary sclerosing cholangitis. N Engl J Med. 1995; 332: 924933
CrossRef | PubMed | Scopus (372)

[87]MacCarty, R.L., LaRusso, N.F., Wiesner, R.H., and Ludwig, J. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology. 1983; 149: 3944
PubMed

[88]Bangarulingam, S.Y., Gossard, A.A., Petersen, B.T., Ott, B.J., and Lindor, K.D. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. Am J Gastroenterol. 2009; 104: 855860
CrossRef | PubMed | Scopus (23)

[89]Berstad, A.E., Aabakken, L., Smith, H.J., Aasen, S., Boberg, K.M., and Schrumpf, E. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2006; 4: 514520
PubMed | Scopus (57)

[90]Angulo, P., Pearce, D.H., Johnson, C.D., Henry, J.J., LaRusso, N.F., Petersen, B.T. et al. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol. 2000; 33: 520527
PubMed

[91]Bjornsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R.W. et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134: 975980
PubMed | Scopus (65)

[92]Broome, U., Glaumann, H., Lindstom, E., Loof, L., Almer, S., Prytz, H. et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol. 2002; 36: 586589
PubMed | Scopus (67)

[93]Angulo, P., Maor-Kendler, Y., and Lindor, K.D. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology. 2002; 35: 14941500
CrossRef | PubMed | Scopus (94)

[94]Bjornsson, E., Boberg, K.M., Cullen, S., Fleming, K., Clausen, O.P., Fausa, O. et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut. 2002; 51: 731735
CrossRef | PubMed | Scopus (79)

[95]Gotthardt, D., Runz, H., Keitel, V., Fischer, C., Flechtenmacher, C., Wirtenberger, M. et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology. 2008; 48: 11571166
CrossRef | PubMed | Scopus (28)

[96]Wilschanski, M., Chait, P., Wade, J.A., Davis, L., Corey, M., St. Louis, P. et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995; 22: 14151422
PubMed

[97]Feldstein, A.E., Perrault, J., El-Youssif, M., Lindor, K.D., Freese, D.K., and Angulo, P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003; 38: 210217
CrossRef | PubMed | Scopus (76)

[98]Gregorio, G.V., Portmann, B., Karani, J., Harrison, P., Donaldson, P.T., Vergani, D. et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001; 33: 544553
CrossRef | PubMed | Scopus (229)

[99]Tanaka, A., Takamori, Y., Toda, G., Ohnishi, S., and Takikawa, H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008; 28: 983989
CrossRef | PubMed | Scopus (8)

[100]Loftus, E.V. Jr., Harewood, G.C., Loftus, C.G., Tremaine, W.J., Harmsen, W.S., Zinsmeister, A.R. et al. PSCIBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 9196
CrossRef | PubMed | Scopus (193)

[101]Soetikno, R.M., Lin, O.S., Heidenreich, P.A., Young, H.S., and Blackstone, M.O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56: 4854
PubMed | Scopus (161)

[102]Broome, U. and Bergquist, A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006; 26: 3141
CrossRef | PubMed

[103]Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Loof, L., Danielsson, A. et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002; 36: 321327
PubMed | Scopus (241)

[104]Lazaridis, K.N. and Gores, G.J. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis. 2006; 26: 4251
CrossRef | PubMed

[105]Harnois, D.M., Gores, G.J., Ludwig, J., Steers, J.L., LaRusso, N.F., and Wiesner, R.H. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer?. J Hepatol. 1997; 27: 512516
PubMed | Scopus (46)

[106]Fevery, J., Verslype, C., Lai, G., Aerts, R., and Van Steenbergen, W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci. 2007; 52: 31233135
CrossRef | PubMed | Scopus (47)

[107]Charatcharoenwitthaya, P., Enders, F.B., Halling, K.C., and Lindor, K.D. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008; 48: 11061117
CrossRef | PubMed | Scopus (75)

[108]Prytz, H., Keiding, S., Bjornsson, E., Broome, U., Almer, S., Castedal, M. et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology. 2006; 44: 15721580
CrossRef | PubMed | Scopus (42)

[109]Boberg, K.M., Jebsen, P., Clausen, O.P., Foss, A., Aabakken, L., and Schrumpf, E. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2006; 45: 568574
PubMed | Scopus (57)

[110]Chazouilleres, O., Poupon, R., Capron, J.P., Metman, E.H., Dhumeaux, D., Amouretti, M. et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990; 11: 120123
PubMed | Scopus (77)

[111]OBrien, C.B., Senior, J.R., Arora-Mirchandani, R., Batta, A.K., and Salen, G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology. 1991; 14: 838847
CrossRef | PubMed | Scopus (106)

[112]Beuers, U., Spengler, U., Kruis, W., Aydemir, U., Wiebecke, B., Heldwein, W. et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992; 16: 707714
CrossRef | PubMed

[113]Stiehl, A. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis. Scand J Gastroenterol Suppl. 1994; 204: 5961
CrossRef | PubMed

[114]Lindor, K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing CholangitisUrsodeoxycholic Acid Study Group. N Engl J Med. 1997; 336: 691695
CrossRef | PubMed | Scopus (353)

[115]Mitchell, S.A., Bansi, D.S., Hunt, N., Von Bergmann, K., Fleming, K.A., and Chapman, R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001; 121: 900907
PubMed

[116]Cullen, S.N., Rust, C., Fleming, K., Edwards, C., Beuers, U., and Chapman, R. High dose ursodeoxycholic acid for the treatment of primary sclerosig cholangitis is safe and effective. J Hepatol. 2008; 48: 792800
Abstract | Full Text | Full Text PDF | PubMed | Scopus (52)

[117]Olsson, R., Boberg, K.M., de Muckadell, O.S., Lindgren, S., Hultcrantz, R., Folvik, G. et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005; 129: 14641472
Abstract | Full Text | Full Text PDF | PubMed | Scopus (139)

[118]Lindor, K.D., Enders, F.B., Schmoll, J.A., Hoskin, T.L., Jorgensen, R.A., Petz, J.L. et al. Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid for primary sclerosing cholangitis. Hepatology. 2008; 48: 378A
CrossRef

[119]Tung, B.Y., Emond, M.J., Haggitt, R.C., Bronner, M.P., Kimmey, M.B., Kowdley, K.V. et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001; 134: 8995
CrossRef | PubMed

[120]Wolf, J.M., Rybicki, L.A., and Lashner, B.A. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005; 22: 783788
CrossRef | PubMed | Scopus (58)

[121]Pardi, D.S., Loftus, E.V. Jr., Kremers, W.K., Keach, J., and Lindor, K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124: 889893
PubMed | Scopus (331)

[122]Rudolph, G., Kloeters-Plachky, P., Rost, D., and Stiehl, A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol. 2007; 19: 487491
CrossRef | PubMed | Scopus (34)

[123]Brandsaeter, B., Isoniemi, H., Broome, U., Olausson, M., Backman, L., Hansen, B. et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004; 40: 815822
PubMed | Scopus (110)

[124]Boberg, K.M., Egeland, T., and Schrumpf, E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol. 2003; 38: 991995
CrossRef | PubMed | Scopus (36)

[125]Etzel, J.P., Eng, S.C., Ko, C.W., Lee, S.D., Saunders, M.D., Tung, B.Y. et al. Complications after ERCP in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2008; 67: 643648
PubMed | Scopus (16)

[126]Andriulli, A., Loperfido, S., Napolitano, G., Niro, G., Valvano, M.R., Spirito, F. et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007; 102: 17811788
CrossRef | PubMed | Scopus (156)

[127]van den Hazel, S.J., Wolfhagen, E.H., van Buuren, H.R., van de Meeberg, P.C., and Van Leeuwen, D.J. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy. 2000; 32: 779782
CrossRef | PubMed | Scopus (31)

[128]Bjornsson, E., Lindqvist-Ottosson, J., Asztely, M., and Olsson, R. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004; 99: 502508
CrossRef | PubMed | Scopus (50)

[129]Hammel, P., Couvelard, A., OToole, D., Ratouis, A., Sauvanet, A., Flejou, J.F. et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med. 2001; 344: 418423
CrossRef | PubMed | Scopus (237)

[130]Stiehl, A., Rudolph, G., Klo-ters-Plachky, P., Sauer, P., and Walker, S. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002; 36: 151156
PubMed | Scopus (123)

[131]Baluyut, A.R., Sherman, S., Lehman, G.A., Hoen, H., and Chalasani, N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001; 53: 308312
PubMed

[132]Johnson, G.K., Geenen, J.E., Venu, R.P., Schmalz, M.J., and Hogan, W.J. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. Gastrointest Endosc. 1991; 37: 3843
PubMed

[133]Stiehl, A., Rudolph, G., Sauer, P., Benz, C., Stremmel, W., Walker, S. et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. J Hepatol. 1997; 26: 560566
PubMed | Scopus (137)

[134]van Milligen de Wit, A.W., Rauws, E.A., van Bracht, J., Mulder, C.J., Jones, E.A., Tytgat, G.N. et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1997; 46: 344347
PubMed | Scopus (30)

[135]Kaya, M., Petersen, B.T., Angulo, P., Baron, T.H., Andrews, J.C., Gostout, C.J. et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001; 96: 10591066
CrossRef | PubMed

[136]Welsh, F.K. and Wigmore, S.J. Roux-en-Y choledochojejunostomy is the method of choice for biliary reconstruction in liver transplantation for primary sclerosing cholangitis. Transplantation. 2004; 77: 602604
CrossRef | PubMed | Scopus (25)

[137]Gordon, F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl. 2006; 12: S73S75
CrossRef | PubMed | Scopus (18)

[138]LaRusso, N.F., Shneider, B.L., Black, D., Gores, G.J., James, S.P., Doo, E. et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006; 44: 746764
CrossRef | PubMed | Scopus (132)

[139]Cholongitas, E., Shusang, V., Papatheodoridis, G.V., Marelli, L., Manousou, P., Rolando, N. et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2008; 14: 138143
CrossRef | PubMed | Scopus (53)

[140]el-Shabrawi, M., Wilkinson, M.L., Portmann, B., Mieli-Vergani, G., Chong, S.K., Williams, R. et al. Primary sclerosing cholangitis in childhood. Gastroenterology. 1987; 92: 12261235
PubMed

[141]Minuk, G.Y., Sutherland, L.R., Pappas, G., Kelly, J.K., and Martin, S.E. Autoimmune chronic active hepatitis (lupoid hepatitis) and primary sclerosing cholangitis in two young adult females. Can J Gastroenterol. 1988; 2: 2227

[142]Rabinovitz, M., Demetris, A.J., Bou-Abboud, C.F., and Van Thiel, D.H. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci. 1992; 37: 16061611
CrossRef | PubMed | Scopus (61)

[143]Lawrence, S.P., Sherman, K.E., Lawson, J.M., and Goodman, Z.D. A 39 year old man with chronic hepatitis. Semin Liver Dis. 1994; 14: 97105
CrossRef | PubMed

[144]Debray, D., Pariente, D., Urvoas, E., Hadchouel, M., and Bernard, O. Sclerosing cholangitis in children. J Pediatr. 1994; 124: 4956
PubMed

[145]Wilschanski, M., Chait, P., Wade, J.A., Davis, L., Corey, M., St. Louis, P. et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995; 22: 14151422
PubMed

[146]Gohlke, F., Lohse, A.W., Dienes, H.P., Lohr, H., Marker-Hermann, E., Gerken, G. et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol. 1996; 24: 699705
PubMed | Scopus (106)

[147]McNair, A.N., Moloney, M., Portmann, B.C., Williams, R., and McFarlane, I.G. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998; 93: 777784
CrossRef | PubMed | Scopus (98)

[148]Al-Chalabi, T., Portmann, B.C., Bernal, W., McFarlane, I.G., and Heneghan, M.A. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008; 28: 209220
CrossRef | PubMed | Scopus (35)

[149]van Buuren, H.R., van Hoogstraten, H.J.E., Terkivatan, T., Schalm, S.W., and Vleggaar, F.P. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000; 33: 543548
CrossRef | PubMed

[150]Kaya, M., Angulo, P., and Lindor, K.D. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000; 33: 537542
PubMed

[151]Floreani, A., Rizzotto, E.R., Ferrara, F., Carderi, I., Caroli, D., Blasone, L. et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005; 100: 15161522
CrossRef | PubMed | Scopus (79)

[152]Abdo, A.A., Bain, V.G., Kichian, K., and Lee, S.S. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002; 36: 13931399
PubMed

[153]Stathopoulos, G., Nourmand, A.D., Blackstone, M., Andersen, D., and Baker, A.L. Rapidly progressive sclerosing cholangitis following surgical treatment of pancreatic pseudotumor. J Clin Gastroenterol. 1995; 21: 143148
CrossRef | PubMed

[154]Erkelens, G.W., Vleggaar, F.P., Lesterhuis, W., van Buuren, H.R., and van der Werf, S.D. Sclerosing pancreato-cholangitis responsive to steroid therapy. Lancet. 1999; 354: 4344
Abstract | Full Text | Full Text PDF | PubMed | Scopus (190)

[155]van Buuren, H.R., Vleggaar, F.P., Willemien Erkelens, G., Zondervan, P.E., Lesterhuis, W., Van Eijck, C.H. et al. Autoimmune pancreatocholangitis: a series of ten patients. Scand J Gastroenterol Suppl. 2006; 243: 7078
CrossRef | PubMed | Scopus (11)

[156]Bjornsson, E., Chari, S.T., Smyrk, T.C., and Lindor, K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology. 2007; 45: 15471554
CrossRef | PubMed | Scopus (97)

[157]Umemura, T., Zen, Y., Hamano, H., Kawa, S., Nakanuma, Y., and Kiyosawa, K. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology. 2007; 46: 463471
CrossRef | PubMed | Scopus (92)

[158]Zen, Y., Fujii, T., Harada, K., Kawano, M., Yamada, K., Takahira, M. et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007; 45: 15381546
CrossRef | PubMed | Scopus (200)

[159]Ghazale, A., Chari, S.T., Zhang, L., Smyrk, T.C., Takahashi, N., Levy, M.J. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008; 134: 706715
Abstract | Full Text | Full Text PDF | PubMed | Scopus (241)

[160]Colombo, C., Battezzati, P.M., Crosignani, A., Morabito, A., Costantini, D., Padoan, R. et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002; 36: 13741382
CrossRef | PubMed | Scopus (0)

[161]Sokol, R.J. and Durie, P.R. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999; 28: S1S13
CrossRef | PubMed | Scopus (116)

[162]Colombo, C., Battezzati, P.M., Podda, M., Bettinardi, N., and Giunta, A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology. 1996; 23: 14841490
CrossRef | PubMed

[163]van de Meeberg, P.C., Houwen, R.H., Sinaasappel, M., Heijerman, H.G., Bijleveld, C.M., and Vanberge-Henegouwen, G.P. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand J Gastroenterol. 1997; 32: 369373
CrossRef | PubMed

[164]Lindblad, A., Glaumann, H., and Strandvik, B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology. 1998; 27: 166174
CrossRef | PubMed | Scopus (94)

[165]Debray, D., Lykavieris, P., Gauthier, F., Dousset, B., Sardet, A., Munck, A. et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999; 31: 7783
PubMed | Scopus (65)

[166]Oude Elferink, R.P., Paulusma, C.C., and Groen, A.K. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology. 2006; 130: 908925
Abstract | Full Text | Full Text PDF | PubMed | Scopus (85)

[167]de Vree, J.M., Jacquemin, E., Sturm, E., Cresteil, D., Bosma, P.J., Aten, J. et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA. 1998; 95: 282287
CrossRef | PubMed | Scopus (401)

[168]Paulusma, C.C., Groen, A., Kunne, C., Ho-Mok, K.S., Spijkerboer, A.L., Rudi de Waart, D. et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology. 2006; 44: 195204
CrossRef | PubMed | Scopus (87)

[169]Strautnieks, S.S., Bull, L.N., Knisely, A.S., Kocoshis, S.A., Dahl, N., Arnell, H. et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998; 20: 233238
CrossRef | PubMed | Scopus (525)

[170]Knisely, A.S., Strautnieks, S.S., Meier, Y., Stieger, B., Byrne, J.A., Portmann, B.C. et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006; 44: 478486
CrossRef | PubMed | Scopus (109)

[171]Trauner, M., Fickert, P., and Wagner, M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis. 2007; 27: 7798
CrossRef | PubMed | Scopus (81)

[172]Jacquemin, E. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: one gene for three diseases. Semin Liver Dis. 2001; 21: 551562
CrossRef | PubMed | Scopus (94)

[173]Whitington, P.F. and Whitington, G.L. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology. 1988; 95: 130136
PubMed

[174]Arnell, H., Bergdahl, S., Papadogiannakis, N., Nemeth, A., and Fischler, B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg. 2008; 43: 13121320
PubMed | Scopus (17)

[175]van Ooteghem, N.A., Klomp, L.W., van Berge-Henegouwen, G.P., and Houwen, R.H. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol. 2002; 36: 439443
PubMed | Scopus (59)

[176]Stapelbroek, J.M., van Erpecum, K.J., Klomp, L.W., Venneman, N.G., Schwartz, T.P., van Berge Henegouwen, G.P. et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology. 2006; 43: 5153
CrossRef | PubMed | Scopus (49)

[177]Piccoli, D.A. and Spinner, N.B. Alagille syndrome and the Jagged1 gene. Semin Liver Dis. 2001; 21: 525534
CrossRef | PubMed | Scopus (59)

[178]Benichou, C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990; 11: 272276
PubMed | Scopus (561)

[179]Andrade, R.J., Lucena, M.I., Fernandez, M.C., Pelaez, G., Pachkoria, K., Garcia-Ruiz, E. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129: 512521
PubMed

[180]Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005; 4: 489499
CrossRef | PubMed | Scopus (344)

[181]Marschall, H.U., Wagner, M., Zollner, G., and Trauner, M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Mol Pharm. 2007; 4: 895910
CrossRef | PubMed | Scopus (12)

[182]Maddrey, W.C. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol. 2005; 39: S83S89
CrossRef | PubMed

[183]Erlinger, S. Drug-induced cholestasis. J Hepatol. 1997; 26: S1S4
PubMed

[184]Navarro, V.J. and Senior, J.R. Drug-related hepatotoxicity. N Engl J Med. 2006; 354: 731739
CrossRef | PubMed | Scopus (326)

[185]Nathwani, R.A. and Kaplowitz, N. Drug hepatotoxicity. Clin Liver Dis. 2006; 10: 207217
PubMed | Scopus (38)

[186]Aithal, P.G. and Day, C.P. The natural history of histologically proved drug induced liver disease. Gut. 1999; 44: 731735
CrossRef | PubMed

[187]Desmet, V.J. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol. 1997; 26: S31S35
PubMed

[188]Lammert, F., Marschall, H.U., Glantz, A., and Matern, S. Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. J Hepatol. 2000; 33: 10121021
PubMed | Scopus (173)

[189]Pusl, T. and Beuers, U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis. 2007; 2: 26
CrossRef | PubMed | Scopus (41)

[190]Glantz, A., Marschall, H.U., and Mattsson, L.A. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004; 40: 467474
CrossRef | PubMed | Scopus (165)

[191]Royal College of Obstetricians and Gynaecologists. Obstetric cholestasis. RCOG Guideline No. 43, 2006:110.

[192]Brites, D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann Hepatol. 2002; 1: 2028
PubMed

[193]Palma, J., Reyes, H., Ribalta, J., Hernandez, I., Sandoval, L., Almuna, R. et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol. 1997; 27: 10221028
PubMed | Scopus (172)

[194]Williamson, C., Hems, L.M., Goulis, D.G., Walker, I., Chambers, J., Donaldson, O. et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG. 2004; 111: 676681
CrossRef | PubMed | Scopus (60)

[195]Lee, R.H., Kwok, K.M., Ingles, S., Wilson, M.L., Mullin, P., Incerpi, M. et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol. 2008; 25: 341345
CrossRef | PubMed | Scopus (19)

[196]Hay, J.E. Liver disease in pregnancy. Hepatology. 2008; 47: 10671076
CrossRef | PubMed | Scopus (80)

[197]Glantz, A., Marschall, H.U., Lammert, F., and Mattsson, L.A. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology. 2005; 42: 13991405
CrossRef | PubMed | Scopus (104)

[198]Kondrackiene, J., Beuers, U., and Kupcinskas, L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005; 129: 894901
PubMed | Scopus (96)

[199]Binder, T., Salaj, P., Zima, T., and Vitek, L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med. 2006; 34: 383391
CrossRef | PubMed | Scopus (42)

[200]Roncaglia, N., Locatelli, A., Arreghini, A., Assi, F., Cameroni, I., Pezzullo, J.C. et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG. 2004; 111: 1721
CrossRef | PubMed | Scopus (53)

[201]Mazzella, G., Nicola, R., Francesco, A., Patrizia, S., Luciano, B., Anna, M. et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology. 2001; 33: 504508
CrossRef | PubMed | Scopus (91)

[202]Kenyon, A.P., Piercy, C.N., Girling, J., Williamson, C., Tribe, R.M., and Shennan, A.H. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG. 2002; 109: 282288
CrossRef | PubMed | Scopus (54)

[203]Roncaglia, N., Arreghini, A., Locatelli, A., Bellini, P., Andreotti, C., and Ghidini, A. Obstetric cholestasis: outcome with active management. Eur J Obstet Gynecol Reprod Biol. 2002; 100: 167170
PubMed | Scopus (52)

[204]Ko, C.W., Beresford, S.A., Schulte, S.J., Matsumoto, A.M., and Lee, S.P. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology. 2005; 41: 359365
CrossRef | PubMed | Scopus (63)

[205]Kahaleh, M., Hartwell, G.D., Arseneau, K.O., Pajewski, T.N., Mullick, T., Isin, G. et al. Safety and efficacy of ERCP in pregnancy. Gastrointest Endosc. 2004; 60: 287292
PubMed | Scopus (59)

[206]Tham, T.C., Vandervoort, J., Wong, R.C., Montes, H., Roston, A.D., Slivka, A. et al. Safety of ERCP during pregnancy. Am J Gastroenterol. 2003; 98: 308311
CrossRef | PubMed | Scopus (71)

[207]Cohen, L.B., Delegge, M.H., Aisenberg, J., Brill, J.V., Inadomi, J.M., Kochman, M.L. et al. AGA Institute review of endoscopic sedation. Gastroenterology. 2007; 133: 675701
PubMed | Scopus (136)

[208]Mahadevan, U. and Kane, S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006; 131: 283311
PubMed | Scopus (59)

[209]Poupon, R., Chretien, Y., Chazouilleres, O., and Poupon, R.E. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol. 2005; 42: 418419
PubMed | Scopus (19)

[210]Hempfling, W., Dilger, K., and Beuers, U. Systematic review: ursodeoxycholic acidadverse effects and drug interactions. Aliment Pharmacol Ther. 2003; 18: 963972
CrossRef | PubMed | Scopus (27)

[211]Park-Wyllie, L., Mazzotta, P., Pastuszak, A., Moretti, M.E., Beique, L., Hunnisett, L. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62: 385392
CrossRef | PubMed | Scopus (267)

[212]Armenti, V.T., Moritz, M.J., Cardonick, E.H., and Davison, J.M. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs. 2002; 62: 23612375
CrossRef | PubMed

[213]Benjaminov, F.S. and Heathcote, J. Liver disease in pregnancy. Am J Gastroenterol. 2004; 99: 24792488
CrossRef | PubMed | Scopus (27)

[214]Kremer, A.E., Beuers, U., Oude-Elferink, R.P., and Pusl, T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008; 68: 21632182
CrossRef | PubMed | Scopus (46)

[215]Datta, D.V. and Sherlock, S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966; 50: 323332
PubMed

[216]Rust, C., Sauter, G.H., Oswald, M., Buttner, J., Kullak-Ublick, G.A., Paumgartner, G. et al. Effect of cholestyramine on bile acid patterns and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest. 2000; 30: 135139
CrossRef | PubMed | Scopus (25)

[217]Khurana, S. and Singh, P. Rifampin is safe for the treatment of pruritus die to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int. 2006; 26: 943948
CrossRef | PubMed | Scopus (44)

[218]Tandon, P., Rowe, B.H., Vandermeer, B., and Bain, V.G. The efficacy and safety of bile acid binding agents, opioid antagonists or rifampicin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007; 102: 15281536
CrossRef | PubMed | Scopus (36)

[219]Bachs, L., Pares, A., Elena, M., Piera, C., and Rodes, J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 1992; 102: 20772080
PubMed

[220]Prince, M.I., Burt, A.D., and Jones, D.E.J. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002; 50: 436439
CrossRef | PubMed | Scopus (87)

[221]Jones, E.A. and Dekker, R.L. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology. 2000; 118: 431432
PubMed

[222]Jones, E.A., Neuberger, J.M., and Bergasa, N.V. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. Q J Med. 2002; 95: 547552
CrossRef

[223]Mayo, M.J., Handem, I., Saldana, S., Jacobe, H., Getachew, Y., and Rush, A.J. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007; 45: 666674
CrossRef | PubMed | Scopus (79)

[224]Pares, A., Cisneros, L., Salmeron, J.M., Caballeria, L., Mas, A., Torras, A. et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004; 99: 11051110
CrossRef | PubMed | Scopus (54)

[225]Pusl, T., Denk, G.U., Parhofer, K.G., and Beuers, U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol. 2006; 45: 887891
PubMed | Scopus (13)

[226]Alallam, A., Barth, D., and Heathcote, E.J. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol. 2008; 22: 505507
PubMed

[227]Beuers, U., Gerken, G., and Pusl, T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology. 2006; 44: 280281
CrossRef | PubMed | Scopus (19)

[228]Gross, C.R., Malinchoc, M., Kim, W.R., Evans, R.W., Wiesner, R.H., Petz, J.L. et al. Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology. 1999; 29: 356364
CrossRef | PubMed | Scopus (105)

[229]Jones, D.E.J. Fatigue in cholestatic liver disease: is it all in the mind?. J Hepatol. 2007; 46: 992994
PubMed | Scopus (6)

[230]Newton, J.L., Pairman, J., Sutcliffe, K., Wilton, K., and Jones, D.E.J. A predictive model for fatigue and its aetiologica associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2008; 6: 228233
PubMed | Scopus (18)

[231]Newton, J.L., Gibson, J.G., Tomlinson, M., Wilton, K., and Jones, D.E.J. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology. 2006; 44: 9198
CrossRef | PubMed | Scopus (57)

[232]Jones, D.E. and Newton, J.L. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther. 2007; 25: 471476
CrossRef | PubMed | Scopus (41)

[233]Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2008 Dec 12. [Epub ahead of print].

[234]Jones, D.E.J., Sutcliffe, K., Pairman, J., Wilton, K., and Newton, J.L. An integrated care pathway improves quality of life in primary biliary cirrhosis. QJM. 2008; 101: 535543
CrossRef | PubMed | Scopus (19)

[235]Pares, A. and Guanabens, N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis. 2008; 12: 407424
PubMed | Scopus (24)

[236]Pereira, S.P., ODonohue, J., Moniz, C., Phillips, M.G., Abraha, H., Buxton-Thomas, M. et al. Transdermal hormone replacement therapy improves veretebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Therap. 2004; 19: 563570
CrossRef | PubMed | Scopus (21)

[237]Boone, R.H., Cheung, A.M., Girlan, M., and Heathcote, E.J. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig Dis Sci. 2006; 51: 11031112
CrossRef | PubMed | Scopus (21)

[238]Guanabens, N., Pares, A., Ros, I., Alvarez, L., Pons, F., Caballeria, L. et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003; 98: 22682274
PubMed

[239]Musialik, J., Petelenz, M., and Gonciarz, Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol. 2005; 40: 873874
CrossRef | PubMed | Scopus (4)

[240]Guanabens, N., Pares, A., del Rio, L., Roca, M., Gomez, R., Munoz, J. et al. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol. 1992; 15: 345349
PubMed | Scopus (40)

[241]Levy, C., Harnois, D.M., Angulo, P., Jorgensen, R., and Lindor, K.D. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005; 25: 117121
CrossRef | PubMed | Scopus (25)

[242]Newton, J.L., Francis, R., Prince, M., James, O.F.W., Bassendine, M.F., Rawlings, D. et al. Osteoporosis in primary biliary cirrhosis revisited. Gut. 2001; 49: 282287
CrossRef | PubMed | Scopus (62)

[243]Gores, G.J., Wiesner, R.H., Dickson, E.R., Zinsmeister, A.R., Jorgensen, R.A., and Langworthy, A. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989; 96: 15521559
PubMed

[244]Jones, D.E.J., Metcalf, J.V., Collier, J.D., Bassendine, M.F., and James, O.F.W. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology. 1997; 26: 11381142
CrossRef | PubMed

[245]Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., and Carey, W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007; 46: 922938
CrossRef | PubMed | Scopus (405)

[246]Bruix, J. and Sherman, M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 12081236
CrossRef | PubMed | Scopus (2344)

[247]Bressler, B., Pinto, R., El-Ashry, D., and Heathcote, E.J. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic creeening for oesophageal varices detection. Gut. 2005; 54: 407410
CrossRef | PubMed | Scopus (37)